Home 2018-03-23T16:25:34+00:00

Why HeRO?

Trends, hard limits, and alarms have been used for years to signal that a patient is currently deteriorating. HeRO is different. HeRO identifies subtle irregularities in heart rate variability that occur hours and days prior to patient deterioration and provides an early warning of patient distress. And unlike any other monitoring technology available, HeRO has been proven in the most rigorous scientific fashion to improve survival 1.

Released very early in infection, cytokines are the mediators of the inflammatory response. They have effects throughout the body, including the way the pacemaker of the heart responds to the autonomic nervous system. During the early stage of infection and other inflammatory events, characteristic abnormal heart rate patterns occur that HeRO has been trained to identify, and HeRO renders a score every hour that is the risk of infection in the next 24 hours2.

There is a large body of literature demonstrating that delays in antibiotic administration can increase mortality and morbidity3,4,5,6. Researchers hypothesized that by improving the timing of the diagnosis, HeRO monitoring might improve outcomes for NICU patients. They conducted the largest ever randomized control trial in neonatology, where 3,003 very low birthweight babies were randomized to either receive standard of care, or standard of care plus HeRO.

For patients in the HeRO monitored group, there was at least an 18 hour average difference in the timing of the rise in HeRO score relative to the diagnosis. And if the antibiotics can be started that much earlier, the infection can be nipped in the bud—before it goes systemic, before organs start shutting down, before the really bad outcomes occur. The HeRO monitored group benefitted from a 22% reduction in mortality. And there was no increase in antibiotic usage for healthy babies7.

Trends and limits tell you what is happening. HeRO is an early warning system that tells you what is going to happen. HeRO…Because timing is critical.

Our Products

Latest News from MPSC

MPSC receives new 510k clearance.

Charlottesville, VA. As MPSC continues to improve the HeRO product portfolio, we are proud to [...]

Medica 2017

November 29, 2017 - MPSC wants to thank the Virginia Economic Development Partnership (@YesVirginia_org) for [...]

MPSC Joins the Patient Safety Movement Foundation’s Open Data Pledge

Charlottesville, VA– June 20th, 2017 MPSC announced today that it signed the Patient Safety Movement’s [...]

PAS Abstracts about HeRO monitoring

At the recently concluded Pediatric Academics Society Annual Conference in San Francisco, there were multiple [...]

CDC urges early detection of sepsis


Cook Children’s using HeRO for early detection.


HeRO thanks Synova for a great NICU Leadership Forum

MPSC is proud to continue supporting the NICU Leadership Forum put on by Synova Associates. [...]

Outcomes based trials – not all outcomes are equal.

Dr. Keith Barrington has a great blog about neonatal research at Neonatal Research. A recent [...]

Contact Us

Toll-free: 800-394-1625
International: +1 434 220 0714
Email: info@heroscore.com

We Support

1 Mortality Reduction by Heart Rate Characteristic Monitoring in Very Low Birth Weight Neonates: A Randomized Trial. Moorman et al. J Pediatrics 2011.
2 HeRO monitoring to reduce mortality in NICU patients. Fairchild KD, Aschner JL. P Research and Reports in Neonatology 2012.
3 Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Kumar et al. Crit Care Med 2006.
4 Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Clec’h et al. Intensive Care Med 2004.
5 Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Lodise et al. Clin Infect Dis 2003.
6 Antibiotic treatment delay and outcome in acute bacterial meningitis. Køster-Rasmussen et al. J Infect 2008.
7 Septicemia mortality reduction in neonates in a heart rate characteristics monitoring trial. Fairchild et al. Pediatr Res 2013.